But because patients in the study received twice-daily pills that circulated ruxolitinib throughout their bodies, rather than topical cream, he said they were “treated systemically with a very toxic drug” that can cause liver and blood problems, infections and other ailments.

但由于参与这项研究的患者每天两次服用鲁索利替尼片剂——而不是涂抹膏剂——药物成分会在整个身体内循环，他认为他们在接受以毒性很强的药物为手段的全身性治疗，该药物有可能让肝脏和血液出问题，还有可能引发感染以及其他疾病。

Although the patients have experienced few side effects, the study is small and not a randomized trial comparing ruxolitinib to other treatments.

尽管患者几乎还没感受到什么副作用，但这项研究规模很小，也并非一次拿鲁索利替尼和其他治疗手段作对比的随机试验。

If ruxolitinib could be applied topically, Dr. Cotsarelis said, “this would be an amazing breakthrough.” Until then, “patients are going to rush in demanding this treatment, and I would not give it.”

柯萨莱利斯博士说，假如可以局部应用鲁索利替尼，“那将是惊人的突破”。在此之前，“要求用该疗法治疗的患者未免显得草率，我是不会给他们开处方的”。

Dr. Raphael Clynes, a co-leader of the research while he was a Columbia professor (he now works for Bristol-Myers Squibb), said the team tested cream and pills on mice, and planned to test a cream on people.

【新药可能让斑秃患者毛发再生】相关文章：

★ 餐厅是怎么引诱我们多花钱的?

★ 别人首先会注意到你哪一点?

★ 食物过敏和食物不耐受的区别是什么?

★ 聪明的人都如何提升效率?

★ 亚马逊的新专利，可能让智能音箱随时监听你讲话

★ 是时候调高空调温度了！室温高有利于提高女性工作效率

★ 马斯克的载人宇宙飞船试运行！你觉得如何？

★ Facebook大股东提供“辍学创业”资金

★ 新研究发现：肚子越大，脑子越小

★ 能自己拨打报警电话的屋子